Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of oral MEK162 in advanced or metastatic cutaneous melanoma with BRAFV600 or NRAS mutations
2010-023412-13Phase 2Completed
- Sponsor
- Array BioPharma
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of binimetinib in cutaneous melanoma (CM), sponsored by Array BioPharma. Primary endpoint: Overall response rate by RECIST. Started Jan 2011; status: completed.
02
Drugs
binimetinib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2010-023412-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023412-13.